The Pharmacy Times® Breast Cancer Resource Center is a comprehensive resource for clinical news and expert insights on issues related to cancers that occur in the breast, including invasive ductal carcinoma, invasive lobular carcinoma, and less common forms of the disease.
November 5th 2024
Using in vitro models, study investigators predict the risk of bone metastasis in breast cancer based on correlations with their in vivo behaviors and potential.
Expert: Cancer Screening Rates in 2021 Remain Lower Than Expected
February 2nd 2022Christopher Mast, MD, vice president of clinical informatics at Epic, discusses research that showed that cancer screening rates in 2021 rebounded from the low rates at the start of the pandemic, but not significantly.
Watch
Pharmacist Medication Insights: Abemaciclib (Verzenio) for Breast Cancer
January 28th 2022Abemaciclib (Verzenio) was recently approved in combination with endocrine therapy for the adjuvant treatment of adult patients with HR–positive, HER2-negative, node-positive, early breast cancer at high risk of recurrence.
Watch
PI3K Inhibitors May Help Prevent Tamoxifen-Associated Uterine Cancer in Patients With Breast Cancer
December 14th 2021Uterine cancers that developed in patients with breast cancer treated with tamoxifen had fewer phosphoinositol-3-kinase (PI3K) pathway mutations and may have been driven by tamoxifen-induced PI3K pathway activation.
Read More
Breast Cancer Patients With Estrogen Receptor Mutations Benefit From Switch to Fulvestrant
December 7th 2021Certain patients with breast cancer treated with an aromatase inhibitor plus palbociclib (Ibrance) could benefit from an early switch to fulvestrant (Faslodex) plus palbociclib, study finds.
Read More
Daily Medication Pearl: Pertuzumab (Perjeta) Injection for Breast Cancer
November 19th 2021Pertuzumab is indicated for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Read More
Daily Medication Pearl: Sacituzumab govitecan-hziy (Trodelvy) for Breast Cancer
November 16th 2021Sacituzumab govitecan-hziy is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received 2 or more prior systemic therapies, at least 1 of which for metastatic disease.
Read More